The KCNAB2 Knockout HCT 116 Polyclonal Cells constitute a CRISPR/Cas9-edited polyclonal knockout population designed for the study of voltage-gated potassium channel ??-subunit function. These cells harbor a targeted disruption of KCNAB2, resulting in loss of Kv??2 protein expression while maintaining the heterogeneous genetic background of the HCT 116 parental line. This polyclonal format avoids clonal artifacts and is suitable for applications requiring representation of tumor cell diversity.
The HCT 116 parental line is a human colorectal carcinoma epithelial cell model harboring a KRAS G13D mutation, MLH1-deficient microsatellite instability (MSI-H) phenotype, and near-diploid karyotype. Widely used in colorectal cancer research, these cells provide a defined genetic context for investigating oncogenic signaling, DNA mismatch repair, and therapeutic resistance.
KCNAB2 encodes Kv??2, a regulatory ??-subunit of voltage-gated potassium (Kv) channels that assembles with pore-forming ??-subunits (KCNA1?CKCNA5) to modulate inactivation kinetics and cell surface trafficking. Kv??2 also contains a putative oxidoreductase domain, suggesting redox-sensing capabilities. Its activity is regulated by membrane depolarization and phosphorylation by PKA and PKC, and its expression is transcriptionally controlled by CREB1. Downstream, Kv??2 influences potassium ion efflux and membrane potential, thereby impacting calcium/calmodulin-dependent cascades and the MAPK1/3 pathway. This culminates in altered cyclin D1 expression and cell cycle progression. Kv??2 interacts with scaffolding proteins DLG1, DLG4, and AKAP5, which organize channel complexes at specific subcellular domains.
In HCT 116 colorectal carcinoma cells, KCNAB2 knockout disrupts ??-subunit regulation of Kv channels, altering membrane potential dynamics and downstream signaling. This provides a powerful system to examine how ion channel modulation influences MAPK pathway activity, cyclin D1 expression, and cell proliferation, particularly in the context of MSI-H and KRAS-driven tumorigenesis. The model can reveal whether KCNAB2 contributes to the aggressive behavior of colorectal tumors and their responses to therapeutic interventions.
Researchers can employ this polyclonal knockout population in diverse functional assays, including patch-clamp electrophysiology to measure potassium current alterations, Western blotting and RT-qPCR for expression analysis, and cell-based assays such as MTT, BrdU incorporation, and transwell migration. Flow cytometry enables detailed cell cycle and apoptosis profiling, while immunofluorescence and co-immunoprecipitation map channel?Cprotein interactions. This model is ideally suited for investigating KCNAB2 as a therapeutic target, exploring potassium channel contributions to chemoresistance, and studying membrane potential-driven signaling in colorectal cancer. For further technical information, please contact Ascent Research.
